Credit: Pixabay
Punjab National Bank
It has reduced its benchmark one-year marginal cost of funds-based lending rate by 0.05 percent to 7.3 percent.
Credit: BCCL
Honeywell Automation India
It reported a fall in its March 2021 quarter net profit to ₹104 crore from ₹111 crore. Revenue fell by over 4 percent to ₹673 crore, year-on-year.
Credit: Honeywell-Automation-India
Cipla
The pharma giant is in talks with the government for clarity and guidance on the roadmap for importing vaccines in the country.
Credit: Cipla
Asian Granito India
Its March 2021 quarter net profit tripled to ₹20 crore while revenue surged by over 68 percent to ₹434 crore, year-on-year.
Credit: Asian-Granito-India
No lockdown, ban gatherings of over 10 people to contain Covid-19 spread: Lancet India task force
No lockdown, ban gatherings of over 10 people to contain Covid-19 spread: Lancet India task force
The Lancet India task force has suggested a complete ban on gatherings of more than 10 persons, and closure of all venues where such gatherings can take place to contain the Covid-19 spread.
advertisement
UPDATED: May 3, 2021 16:10 IST
Lancet India task force has suggested a ban on gathering of more than 10 people to contain Covid-19 spread (AP photo)
The Lancet India Task Force on Covid-19 has suggested a containment measures checklist to the central government to contain the frightening surge in the Covid-19 cases. The task force has also asserted that these measures must be done beyond the current binary discussion on a lockdown .
Can t ramp up vaccine production overnight, says SII chief Adar Poonawalla
Serum Institute of India chief Adar Poonawalla on Monday said that vaccine manufacturing is a spcialised process and as such the production can’t be ramped up overnight. He further added that his firm has received total orders of over 26 crore doses, of which 15 crore doses have been supplied, and 11 crore doses will be supplied in the next few months.
advertisement
UPDATED: May 3, 2021 22:00 IST
SII CEO Poonawalla said the population of India is huge and to produce enough doses for all adults is not an easy task. (File Photo)
Covishield production in full swing, will return to India in few days, says SII s Adar Poonawalla fr
Covishield production in full swing, will return to India in few days, says SII s Adar Poonawalla from London
Serum Institute s Adar Poonawalla, who is currently in the UK to meet his family members, has said he will return to India in a few days. The SII CEO also has said that the production of Covid vaccine Covishield is in full swing in Pune and that he will review the operations once he is back in India.
advertisement
UPDATED: May 2, 2021 09:55 IST
Adar Poonawalla of the Serum Institute of India, which manufactures the AstraZeneca Covid vaccine. (File Pohoto)